|
|
|
|
| LEADER |
04586nma a2201009 u 4500 |
| 001 |
EB002050980 |
| 003 |
EBX01000000000000001194646 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a books978-3-0365-4278-2
|
| 020 |
|
|
|a 9783036542775
|
| 020 |
|
|
|a 9783036542782
|
| 100 |
1 |
|
|a Nowaczyk, Alicja
|
| 245 |
0 |
0 |
|a Neurotransmitter-Related Molecular Modeling Studies
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (188 p.)
|
| 653 |
|
|
|a risk factors
|
| 653 |
|
|
|a orthostatic hypotension
|
| 653 |
|
|
|a guanylate cyclase (GC)
|
| 653 |
|
|
|a halogenated pyrazolines
|
| 653 |
|
|
|a serotonin and dopamine in fibromyalgia
|
| 653 |
|
|
|a depression
|
| 653 |
|
|
|a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
|
| 653 |
|
|
|a cognitive impairment
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a dementia
|
| 653 |
|
|
|a neurotransmitters
|
| 653 |
|
|
|a monoamine oxidase inhibitors
|
| 653 |
|
|
|a adverse drug reaction
|
| 653 |
|
|
|a SGLT2i
|
| 653 |
|
|
|a molecular dynamics
|
| 653 |
|
|
|a ECG study
|
| 653 |
|
|
|a genetic polymorphisms
|
| 653 |
|
|
|a mixed dyslipidemia
|
| 653 |
|
|
|a reversibility
|
| 653 |
|
|
|a chronic heart failure (CHF)
|
| 653 |
|
|
|a neuroprotection
|
| 653 |
|
|
|a BDNF
|
| 653 |
|
|
|a dysautonomia
|
| 653 |
|
|
|a tiagabine
|
| 653 |
|
|
|a ropinirole
|
| 653 |
|
|
|a neurodegenerative diseases
|
| 653 |
|
|
|a atheroprotection
|
| 653 |
|
|
|a type 2 diabetes mellitus
|
| 653 |
|
|
|a levodopa
|
| 653 |
|
|
|a mTOR
|
| 653 |
|
|
|a 5-HT receptors
|
| 653 |
|
|
|a gastrointestinal tract
|
| 653 |
|
|
|a glutamate
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a kinetics
|
| 653 |
|
|
|a acetylcholine
|
| 653 |
|
|
|a neurotoxicity
|
| 653 |
|
|
|a white matter hyperintensities
|
| 653 |
|
|
|a pulmonary arterial hypertension (PAH)
|
| 653 |
|
|
|a cardiac voltage-gated ion channels
|
| 653 |
|
|
|a renin-angiotensin system
|
| 653 |
|
|
|a stroke
|
| 653 |
|
|
|a dopamine
|
| 653 |
|
|
|a statins
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a androgenetic alopecia
|
| 653 |
|
|
|a molecular modeling
|
| 653 |
|
|
|a serotonin
|
| 653 |
|
|
|a mouse
|
| 653 |
|
|
|a vortioxetine
|
| 653 |
|
|
|a antibiotics
|
| 653 |
|
|
|a neurotransmission
|
| 653 |
|
|
|a sodium-glucose cotransporter 2 inhibitors
|
| 653 |
|
|
|a Chemistry / bicssc
|
| 653 |
|
|
|a reserpine-induced fibromyalgia model
|
| 700 |
1 |
|
|a Grześk, Grzegorz
|
| 700 |
1 |
|
|a Nowaczyk, Alicja
|
| 700 |
1 |
|
|a Grześk, Grzegorz
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-4278-2
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5731
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/87533
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 000
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 540
|
| 082 |
0 |
|
|a 380
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo-exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson's disease) and contribute to the occurrence of dementia (including Alzheimer's disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.
|